Pyridazinone-amides derivatives

1. A compound of formula (I):

wherein Ra is H, Hal or Al, wherein Hal is F, Cl, Br, or I, and wherein Al is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more H atoms may be replaced by Hal, ORb, COORb, CN or N(Rb) 2 and wherein one or more CH 2 -groups may be replaced by O, CO, NRb or S, SO, SO 2 , 1,2-, 1,3- or 1,4- phenylen, —CH═CH— or —C══C—,

wherein Rb is H or alkyl,

wherein R1 is H, Hal or Al, and

wherein Z is a group:

wherein in said group:

X is CH or N,

Y is CH or N, and

Rc is H, Hal or Al,

and a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or stereoisomer thereof.

2. The compound of Formula (I) according to claim 1 , wherein Ra is Hal, ORd, or alkyl, and wherein Rd is H, alkyl or COH or COalkyl.

3. The compound of Formula (I) according to claim 1 , wherein R1 denotes H, alkyl, Hal, Oalkyl, ORd, (CH 2 )nCONHRb or (CH2)nCOORb, wherein n is 0, 1, 2, 3, 4, 5, or 6 and Rd is H, alkyl or CORb.

4. The compound of Formula (I) according to claim 1 , wherein Z is pyridinyl or pyrimidinyl.

5. The compound of Formula (I) according to claim 1 , selected from the group consisting of compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or stereoisomer thereof,

wherein compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 are:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

6. A pharmaceutical composition, comprising:

the compound of Formula (I) according to claim 1 and a pharmaceutically acceptable solvate, salt, hydrate or stereoisomer thereof, including mixtures thereof in all ratios.

7. A method for the treatment of rheumatoid arthritis, lupus nephritis, and systemic lupus erythematosus comprising administering the composition according to claim 6 to a subject in need thereof.